Representative trials: (i) CD19/GD2 CAR- γδ lysed malignant B cell and neuroectodermal cell lines showing enhanced cytotoxicity with CD69 and IFNα upregulation (137); (ii) γδ CD19 CAR-iT inhibited NALM-6 B cell lymphoma tumor growth and lysed cells in vitro and in vivo (138). The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.